VEGFA and non-small cell lung carcinoma: A variety of targeting agents such as an antibody against the vascular endothelial growth factor (VEGF) and TKIs of the epidermal growth factor receptor (EGFR) are now tested in clinical trials for resectable NSCLC patients, but these agents can cause unexpected bleeding or delayed wound healing which may lead to increased morbidity and mortality.